ES3042376T3 - Stable formulations of indocyanine green - Google Patents
Stable formulations of indocyanine greenInfo
- Publication number
- ES3042376T3 ES3042376T3 ES22714185T ES22714185T ES3042376T3 ES 3042376 T3 ES3042376 T3 ES 3042376T3 ES 22714185 T ES22714185 T ES 22714185T ES 22714185 T ES22714185 T ES 22714185T ES 3042376 T3 ES3042376 T3 ES 3042376T3
- Authority
- ES
- Spain
- Prior art keywords
- indocyanine green
- composition
- histidine
- aqueous
- icg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305324 | 2021-03-17 | ||
| PCT/EP2022/056446 WO2022194734A1 (en) | 2021-03-17 | 2022-03-14 | Stable formulations of indocyanine green |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3042376T3 true ES3042376T3 (en) | 2025-11-20 |
Family
ID=75302476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22714185T Active ES3042376T3 (en) | 2021-03-17 | 2022-03-14 | Stable formulations of indocyanine green |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240156991A1 (enExample) |
| EP (1) | EP4308076B1 (enExample) |
| JP (1) | JP2024510501A (enExample) |
| CN (1) | CN117098532A (enExample) |
| BR (1) | BR112023018929A2 (enExample) |
| ES (1) | ES3042376T3 (enExample) |
| WO (1) | WO2022194734A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4308082A1 (en) * | 2021-03-17 | 2024-01-24 | Provepharm Life Solutions | Stable formulations of indocyanine green |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08509260A (ja) * | 1993-04-20 | 1996-10-01 | マリンクロット・メディカル・インコーポレイテッド | 電圧感受性染料の安定化 |
| FR2710060B1 (fr) | 1993-09-17 | 1995-11-17 | Rech Biolog Et | Procédé de préparation de benz[e]indoles substitués de pureté élevée et leurs sels alcalins. |
| US6944493B2 (en) * | 1999-09-10 | 2005-09-13 | Akora, Inc. | Indocyanine green (ICG) compositions and related methods of use |
| CA2635975A1 (en) * | 2006-01-04 | 2007-07-12 | Do-Coop Technologies Ltd. | Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents |
| DE102007030403A1 (de) | 2007-06-29 | 2009-01-08 | Universität Bielefeld | Verfahren zur Verbesserung der Photostabilität von Fluoreszenzfarbstoffen |
| CN103301482B (zh) | 2013-06-27 | 2014-12-17 | 深圳先进技术研究院 | 两亲性三嵌段聚多肽载icg胶束及其制备方法 |
| JP6623479B2 (ja) | 2015-02-08 | 2019-12-25 | トンリ・バイオメディカル・カンパニー・リミテッド | 脂質ナノ粒子及びその使用 |
| CA3021809A1 (en) * | 2015-05-11 | 2016-11-17 | Dicronis Sagl | Compositions for circulatory system visualization |
| DK3383436T3 (da) | 2015-12-01 | 2023-11-20 | Dishman Carbogen Amcis Ltd | Forbedret fremgangsmåde til fremstilling af indocyaningrønt |
| US20190337896A1 (en) | 2018-05-02 | 2019-11-07 | Biophore India Pharmaceuticals Pvt. Ltd. | PROCESS FOR THE PREPARATION OF SODIUM 4-(2-((1E,3E,5E,7Z)-7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO[e]INDOL-2(3H)-YLIDENE) HEPTA-1,3,5-TRIENYL)-1,1-DIMETHYL-1H-BENZO[e]INDOLIUM-3-YL) BUTANE-1-SULFONATE (INDOCYANINE GREEN) |
| WO2020240514A1 (en) | 2019-05-30 | 2020-12-03 | Leiutis Pharmaceuticals Pvt, Ltd. | Stable formulations of indocyanine green |
-
2022
- 2022-03-14 JP JP2023557349A patent/JP2024510501A/ja active Pending
- 2022-03-14 ES ES22714185T patent/ES3042376T3/es active Active
- 2022-03-14 BR BR112023018929A patent/BR112023018929A2/pt unknown
- 2022-03-14 WO PCT/EP2022/056446 patent/WO2022194734A1/en not_active Ceased
- 2022-03-14 US US18/549,378 patent/US20240156991A1/en active Pending
- 2022-03-14 EP EP22714185.0A patent/EP4308076B1/en active Active
- 2022-03-14 CN CN202280022011.2A patent/CN117098532A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4308076A1 (en) | 2024-01-24 |
| EP4308076B1 (en) | 2025-07-16 |
| CN117098532A (zh) | 2023-11-21 |
| BR112023018929A2 (pt) | 2023-10-10 |
| JP2024510501A (ja) | 2024-03-07 |
| WO2022194734A1 (en) | 2022-09-22 |
| US20240156991A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2258661T3 (es) | Formulaciones farmaceuticas con un derivado de platino. | |
| KR101194123B1 (ko) | 패수딜 함유 제제 및 그 안정성을 개선하는 방법 | |
| PT1687031E (pt) | Preparação farmacêutica contendo um anticorpo contra o receptor do egf | |
| ES2905729T3 (es) | Disolución de galato de epigalocatequina | |
| US20120208887A1 (en) | Stable, liquid, ready-to-use ketoprofen formulations | |
| WO2012004438A1 (es) | Una formulación farmacéutica inyectable de melfalano | |
| EA008908B1 (ru) | Инъецируемый жидкий состав парацетамола | |
| US20100249413A1 (en) | Stabilized pharmaceutical composition | |
| FI101597B (fi) | Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi pot ilaan valodynaamisessa hoidossa tai diagnosoinnissa | |
| CN116997325B (zh) | 稳定的吲哚菁绿制剂 | |
| EP4308076B1 (en) | Stable formulations of indocyanine green | |
| ES2904505T3 (es) | Formulación líquida de cabazitaxel | |
| KR20060051135A (ko) | 안정화된 주사용 수용액 제재 | |
| CN117062597B (zh) | 稳定的吲哚菁绿制剂 | |
| ES2344674B1 (es) | Composicion farmaceutica inyectable de taxanos. | |
| ES2292781T3 (es) | Formulacion galenica inyectable para utilizar en un diagnostico o una terapia fotodinamica y su procedimiento de preparacion. | |
| MXPA94002884A (es) | Composicion acuosa estable durante el almacenamiento y metodo para hacer la misma. | |
| JP3668225B2 (ja) | Oct製剤 | |
| CA2486571C (en) | Pharmaceutical composition | |
| CN114144186A (zh) | 含有对硼基苯丙氨酸的药物组合物及其制造方法 | |
| US20230381222A1 (en) | Lyophilized pharmaceutical compositions of copper histidinate | |
| HK1252534A1 (zh) | 来氟米林的可注射药物组合物 |